The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
Labcorp and the Alliance for Clinical Trials in Oncology will collaborate on a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer.
